Market Overview:
The global T-cell immunotherapy market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of cancer, technological advancements in T-cell immunotherapy, and rising investments by key players in this market. The global T-cell immunotherapy market can be segmented on the basis of type into CAR-T therapies, TCR therapies, and TIL therapies. The CAR-T therapy segment is expected to account for the largest share of the global T-cell immunotherapy market during the forecast period. This segment is expected to grow at a CAGR of XX% during the forecast period. The growth in this segment can be attributed to factors such as increasing number of clinical trials for CAR-T therapy and rising demand for personalized cancer treatments. On the basis of application,the global t cell Immunotherapy Market can be divided into stomach cancer, lung cancer colorectal cancer esophagus cancer pancreaticcancer others).
Product Definition:
T-cell immunotherapy is a type of cancer treatment that uses T cells to fight cancer. T cells are a type of white blood cell that helps the body fight infection. Immunotherapy is a type of treatment that uses the body's own immune system to fight disease.
CAR-T:
Cell-based therapies are a new approach in cancer treatment. This therapy is based on the principle that cancer cells can be treated as infectious microorganisms and destroyed by the immune system. The therapy includes extracting T-cells from the patient's blood, engineering them to target and kill specific cancer cells, then putting those modified T-cells back into the patient's body.
TCR:
TCR is a protein that acts as a key immune cell receptor. It is found on the membranes of most cells and plays an important role in determining the type of immune response mounted by the cell. TCR can be studied under a microscope and consists of two domains: an extracellular domain that determines where the protein binds, and an intracellular domain that carries out the binding.
Application Insights:
The other applications segment includes kidney cancer, liver cancer, breast cancer and prostate cancer. The market for kidney and liver cancers is expected to witness significant growth over the forecast period owing to the increasing incidence of these types of cancers. T-cell immunotherapy is also being studied as a potential treatment option for pancreatic and esophagus cancers. However, due to lack of awareness about this therapy among healthcare professionals and patients there are very few cases where this therapy has been used so far.
Stomach Cancer was the most prominent application in terms of revenue in 2017 owing to an increase in incidence rates coupled with high survival rates associated with this type of tumor worldwide. According to data published by WHO, stomach carcinoma accounted for 7%of all gastrointestinal malignant tumors across the globe in 2018 which amounted to around 6050 cases globally that year alone which were treated via T-Cell Immunotherapy at that time.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high investment in R&D, and increasing adoption of immunotherapy drugs for treatment. The U.S., which is at the forefront, has witnessed an exponential rise in approvals and product launches over the past few years with more than 200 new T-cell therapies have been approved since 2011 (excluding biosimilars). In addition to this, there are around 1 million people living with cancer who would benefit from these treatments but are not able to access them due to financial constraints or geographical location.
Asia Pacific is expected to witness lucrative growth during the forecast period owing its growing economy coupled with increased government spending on healthcare research & development as well as rising incidence rates for cancers that require effective treatment options only available through immunotherapy drugs like T-cell therapy products.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the T-cell immunotherapy market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for T-cell immunotherapy products and services over the next few years.
- Rising awareness about T-cell immunotherapy: The rising awareness about T-cell immunotherapy among patients and healthcare professionals is another major factor driving its growth worldwide. This therapy has been shown to be more effective than other treatments available for various types of cancers such as melanoma, leukemia, lymphoma, and others. As a result, there is an increasing demand for these therapies from patients across the globe which is likely to boost market growth in coming years
Scope Of The Report
Report Attributes
Report Details
Report Title
T-Cell Immunotherapy Market Research Report
By Type
CAR-T, TCR, TIL Therapies
By Application
Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer, Others
By Companies
Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Kite Pharma, Novartis, Takara Bio, Unum Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global T-Cell Immunotherapy Market Report Segments:
The global T-Cell Immunotherapy market is segmented on the basis of:
Types
CAR-T, TCR, TIL Therapies
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Adaptimmune
- Altor Bioscience Corporation
- Cellectis
- Juno Therapeutics
- Kite Pharma
- Novartis
- Takara Bio
- Unum Therapeutics
Highlights of The T-Cell Immunotherapy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CAR-T
- TCR
- TIL Therapies
- By Application:
- Stomach Cancer
- Lung Cancer
- Colorectal Cancer
- Esophagus Cancer
- Pancreatic Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the T-Cell Immunotherapy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
T-Cell Immunotherapy is a treatment for cancer that uses the body's own immune system to fight the disease. This approach involves using T cells, which are white blood cells that help protect the body from infection. Researchers use T-cell immunotherapy to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma.
Some of the key players operating in the t-cell immunotherapy market are Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Kite Pharma, Novartis, Takara Bio, Unum Therapeutics.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. T-Cell Immunotherapy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. T-Cell Immunotherapy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. T-Cell Immunotherapy Market - Supply Chain
4.5. Global T-Cell Immunotherapy Market Forecast
4.5.1. T-Cell Immunotherapy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. T-Cell Immunotherapy Market Size (000 Units) and Y-o-Y Growth
4.5.3. T-Cell Immunotherapy Market Absolute $ Opportunity
5. Global T-Cell Immunotherapy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. T-Cell Immunotherapy Market Size and Volume Forecast by Type
5.3.1. CAR-T
5.3.2. TCR
5.3.3. TIL Therapies
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global T-Cell Immunotherapy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. T-Cell Immunotherapy Market Size and Volume Forecast by Application
6.3.1. Stomach Cancer
6.3.2. Lung Cancer
6.3.3. Colorectal Cancer
6.3.4. Esophagus Cancer
6.3.5. Pancreatic Cancer
6.3.6. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global T-Cell Immunotherapy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. T-Cell Immunotherapy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global T-Cell Immunotherapy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. T-Cell Immunotherapy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global T-Cell Immunotherapy Demand Share Forecast, 2019-2026
9. North America T-Cell Immunotherapy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America T-Cell Immunotherapy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America T-Cell Immunotherapy Market Size and Volume Forecast by Application
9.4.1. Stomach Cancer
9.4.2. Lung Cancer
9.4.3. Colorectal Cancer
9.4.4. Esophagus Cancer
9.4.5. Pancreatic Cancer
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America T-Cell Immunotherapy Market Size and Volume Forecast by Type
9.7.1. CAR-T
9.7.2. TCR
9.7.3. TIL Therapies
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America T-Cell Immunotherapy Demand Share Forecast, 2019-2026
10. Latin America T-Cell Immunotherapy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America T-Cell Immunotherapy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America T-Cell Immunotherapy Market Size and Volume Forecast by Application
10.4.1. Stomach Cancer
10.4.2. Lung Cancer
10.4.3. Colorectal Cancer
10.4.4. Esophagus Cancer
10.4.5. Pancreatic Cancer
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America T-Cell Immunotherapy Market Size and Volume Forecast by Type
10.7.1. CAR-T
10.7.2. TCR
10.7.3. TIL Therapies
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America T-Cell Immunotherapy Demand Share Forecast, 2019-2026
11. Europe T-Cell Immunotherapy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe T-Cell Immunotherapy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe T-Cell Immunotherapy Market Size and Volume Forecast by Application
11.4.1. Stomach Cancer
11.4.2. Lung Cancer
11.4.3. Colorectal Cancer
11.4.4. Esophagus Cancer
11.4.5. Pancreatic Cancer
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe T-Cell Immunotherapy Market Size and Volume Forecast by Type
11.7.1. CAR-T
11.7.2. TCR
11.7.3. TIL Therapies
11.8. Bass Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe T-Cell Immunotherapy Demand Share, 2019-2026
12. Asia Pacific T-Cell Immunotherapy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific T-Cell Immunotherapy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific T-Cell Immunotherapy Market Size and Volume Forecast by Application
12.4.1. Stomach Cancer
12.4.2. Lung Cancer
12.4.3. Colorectal Cancer
12.4.4. Esophagus Cancer
12.4.5. Pancreatic Cancer
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific T-Cell Immunotherapy Market Size and Volume Forecast by Type
12.7.1. CAR-T
12.7.2. TCR
12.7.3. TIL Therapies
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific T-Cell Immunotherapy Demand Share, 2019-2026
13. Middle East & Africa T-Cell Immunotherapy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa T-Cell Immunotherapy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa T-Cell Immunotherapy Market Size and Volume Forecast by Application
13.4.1. Stomach Cancer
13.4.2. Lung Cancer
13.4.3. Colorectal Cancer
13.4.4. Esophagus Cancer
13.4.5. Pancreatic Cancer
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa T-Cell Immunotherapy Market Size and Volume Forecast by Type
13.7.1. CAR-T
13.7.2. TCR
13.7.3. TIL Therapies
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa T-Cell Immunotherapy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global T-Cell Immunotherapy Market: Market Share Analysis
14.2. T-Cell Immunotherapy Distributors and Customers
14.3. T-Cell Immunotherapy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Adaptimmune
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Altor Bioscience Corporation
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cellectis
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Juno Therapeutics
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Kite Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Takara Bio
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Unum Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
